Other additional anti-CD47 antibodies include IBI-88 (Letaplimab), AK117 (Ligufalimab), and TJ011133 (Lemzoparlimab) which are currently being investigated in combination therapies for the treatment of NHL, MDS, and AML. This evidence concerns the gene CD47 and acute myeloid leukemia.